October 17, 2019
Inversago Pharma adds to its Board of Directors
Inversago has welcomed Dennis Kim, MD, MBA and Tara Nickerson, PhD, MBA as new independent directors, following its goal to…
Pharmaceuticals, Biotechnology and Life Sciences
Category: Regions
October 17, 2019
Cadent Therapeutics displays its lead asset’s testing progress, with new medical boss named
Cadent Therapeutics has named Dawn Wilson appointed as Vice President, Clinical Operations, as it releases the data from Phase 2…
October 17, 2019
FDA grants Orphan Drug Designation for Neuren’s NNZ-2591 to treat Angelman, Phelan-McDermid and Pitt Hopkins syndromes
MELBOURNE, Australia–(BUSINESS WIRE)–Neuren Pharmaceuticals (ASX: NEU) today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug…
October 17, 2019
Plexium launches with $28 Million in series A financing
San Diego based Plexium on Thursday launched the company with $28 Million in series A financing, aimed for advance its DELPhe platform to discover novel E3 ligase-modulating therapeutics to treat cancer and neurodegenerative diseases.
October 17, 2019
Sensorion has the last patient’s last visit in SENS-111 phase 2 clinical trial
Out of 105 patients were enrolled and treated in Sensorion’s SENS-111 Phase 2 trial, the last patient’s last visit of…
October 16, 2019
Roche reports 10% rise in group sales for nine months 2019
Roche on Wednesday reported 10% raise in sales in the third yearly quarter of 2019, backed by new products, while its Pharmaceuticals Division sales went up 12%, driven by high demand for recently launched medicines, mainly Ocrevus, Hemlibra, Tecentriq and Perjeta.
October 16, 2019
U.S. FDA Advisory Committee recommends approval of cefiderocol for treatment of complicated urinary tract infections
Shinogoi might have cefiderocol approved by the US FDA, as the Advisory Committee reccomends it for treatment of complicated urinary…
October 16, 2019
Boehringer Ingelheim Announces First Patient Enrolled in Phase II Trial of Novel Cystic Fibrosis Treatment (BALANCE-CFTM 1)
-Boehringer Ingelheim is enrolling first patient to test nvestigational compound BI ENaC inhibitor delivered twice daily via the Respimat, a…
October 16, 2019
Bicycle Therapeutics presents data for its lead Bicycle Toxin Conjugate (BTC) product candidate
CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics plc (NASDAQ: BCYC) a clinical-stage biotechnology company pioneering a new and differentiated class of…